Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex

da | postato in: Senza categoria | 0

A phase one dose-finding and safety study in humans of TMC278
LA, a long-acting, injectable formation of the antiretroviral (ARV) drug
rilpivirine, found that a single 1200-mg dose could produce sustained drug levels
in rectal tissues that could offer protection against HIV for three months, and
did in fact suppress viral replication in so-called